Pharmaceuticals

Injectable Targeted Therapy Industry Growth Insights: Revenue Forecast to 2030

February 16, 2026March 11, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the injectable targeted therapy market from 2026–2035 with trusted insights from The Business Research Company

How much is the Injectable Targeted Therapy Market valued at in 2026, and what valuation is forecast for 2030?

The injectable targeted therapy market size has experienced significant expansion recently. It is projected to increase from $64.22 billion in 2025 to $71.03 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.6%. This historical growth can be ascribed to rising cancer incidence rates, advancements in monoclonal antibody development, the increasing adoption of biologic therapies, the expansion of oncology treatment centers, and intensified clinical research activity in targeted drugs.

The injectable targeted therapy market size is projected to undergo substantial growth in the coming years. This market is expected to reach $105.2 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.3%. The anticipated expansion during the forecast period can be attributed to several factors, including the increasing approvals of targeted injectable therapies, rising investments in personalized medicine, the expansion of biologics manufacturing capacity, a growing focus on immunotherapy development, and the increasing demand for precision treatment protocols. Key trends observed in this period encompass the escalating development of precision oncology injectables, a rising adoption of antibody-based therapeutics, an intensifying focus on targeted drug delivery systems, the broadening of combination injectable therapies, and an enhanced emphasis on minimizing off-target toxicity.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28250&type=smp

What Drivers Are Influencing The Growth Of The Injectable Targeted Therapy Market?

The rising demand for personalized medicine is anticipated to drive the expansion of the injectable targeted therapy market moving forward. Personalized medicine defines a healthcare methodology that adapts prevention, diagnosis, and treatment according to an individual’s genetic makeup, environmental factors, and lifestyle. The growth of personalized medicine is propelled by advancements in genomics, which allow for a more profound comprehension of individual genetic variations, enabling more precise, targeted therapies that enhance patient outcomes and minimize trial-and-error approaches. Injectable targeted therapy supports personalized medicine by delivering medications specifically tailored to a patient’s unique molecular or genetic disease profile, thereby improving effectiveness and reducing adverse effects. For instance, in February 2024, data from the Personalized Medicine Coalition, a US-based non-profit organization, indicated that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, an increase from six in 2022. The newly approved personalized treatments for 2023 also encompassed seven cancer drugs and three for other diseases and conditions. Thus, the escalating demand for personalized medicine is a key driver for the growth of the injectable targeted therapy market.

What Segments Are Included Within The Injectable Targeted Therapy Market?

The injectable targeted therapy market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Small-Molecules, Immunotoxins, Other Types

2) By Mechanism Of Action: Targeted Inhibition of Signal Transduction Pathways, Targeted Delivery Of Cytotoxic Agents, Immunomodulation

3) By Route Of Administration: Intravenous, Subcutaneous, Intramuscular

4) By Application: Oncology, Cardiometabolism, Immunology, Infectious Diseases, Neuroscience, Ophthalmology, Other Applications

5) By End User: Hospitals, Specialty Clinics, Research Laboratories

Subsegments:

1) By Monoclonal Antibodies: Fully Human Antibodies, Humanized Antibodies, Chimeric Antibodies

2) By Small-Molecules: Tyrosine Kinase Inhibitors, Proteasome Inhibitors, Mtor Inhibitors

3) By Immunotoxins: Recombinant Immunotoxins, Chemical Conjugates, Fusion Proteins

4) By Other Types: Antibody-Drug Conjugates, Bispecific Antibodies, Peptide-Based Therapeutics

What Trends Are Expected To Impact The Competitive Landscape Of The Injectable Targeted Therapy Market?

Leading companies in the injectable targeted therapy market are focused on developing innovative solutions, such as subcutaneous injection, to enhance drug delivery efficiency, improve patient compliance, and more effectively target specific disease pathways. A subcutaneous injection is a method of administering medication under the skin into the fatty tissue just beneath the dermis, allowing for slow absorption of the drug into the bloodstream. For instance, in August 2025, Eisai Co., Ltd., a Japan-based pharmaceutical company, partnered with Biogen Inc., a US-based biotechnology company, and obtained approval from the FDA for LEQEMBI IQLIK, a treatment for early Alzheimer’s disease. This is a convenient, once-weekly subcutaneous injection for the maintenance treatment of early Alzheimer’s disease, allowing patients to self-administer at home after initial intravenous therapy. It works by targeting and clearing amyloid beta plaques and protofibrils, which are key drivers of Alzheimer’s progression, thereby helping to slow cognitive decline. This formulation reduces treatment time, minimizes systemic side effects compared to IV infusions, and decreases the need for infusion center visits, providing greater independence for patients and care partners.

Who Are The Top-Performing Companies In The Injectable Targeted Therapy Market In Recent Years?

Major companies operating in the injectable targeted therapy market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA, Novartis AG, AstraZeneca plc, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Eisai Co. Ltd., Genentech Inc., Beigene Ltd., Agenus Inc., Xilio Therapeutics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/injectable-targeted-therapy-global-market-report

Which Region Currently Holds The Largest Share Of The Injectable Targeted Therapy Market?

North America was the largest region in the injectable targeted therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the injectable targeted therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Injectable Targeted Therapy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=28250&type=smp

Browse Through More Reports Similar to the Global Injectable Targeted Therapy Market 2026, By The Business Research Company

Targeted Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report

Patient Controlled Injectors Market Report 2026

https://www.thebusinessresearchcompany.com/report/patient-controlled-injectors-global-market-report

Injectable Drug Delivery Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/injectable-drug-delivery-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795